<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525705</url>
  </required_header>
  <id_info>
    <org_study_id>2009_42/1004</org_study_id>
    <secondary_id>2010-A00217-32</secondary_id>
    <nct_id>NCT02525705</nct_id>
  </id_info>
  <brief_title>Dumping Syndrome After Operation of Esophageal Atresia Type III</brief_title>
  <acronym>DUMPING</acronym>
  <official_title>Frequency of Occurrence of Dumping Syndrome After Operation of Esophageal Atresia Type III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prevalence at 3.5 months of age of dumping
      syndrome in children operated at birth for oesophageal atresia type III et IV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients with type III and IV oesophageal atresia that are born in 8 different
      centers in France and Sydney (Australia) are included in the study, if willing. As soon as
      they weigh more than 4.150kg and if they are still younger than 3.5 months, an Oral Glucose
      Tolerance Test (OGTT) is performed. Glycemia and insulinemia are monitored every 30 minutes
      from intake to 240 minutes. Clinical signs that are presented are noted. If early
      hyperglycemia or late hypoglycemia are biologically or clinically observed, ascarbose
      treatment is initiated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early hyperglycemia during Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>up to 240 min</time_frame>
    <description>Hypoglycemia : glycemia &lt; 0,6 g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late hypoglycemia during OGTT</measure>
    <time_frame>up to 240 min</time_frame>
    <description>Hyperglycemia : &gt; 1,8g/L from H0 to 30 min after oral intake, &gt; 1.7 between 1 and 2 h ours, &gt; 1.4 between 2 and 3 h
, &gt; 1, 26 after 3 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical signs presenting consequently to OGTT</measure>
    <time_frame>continuous monitoring during 240 minutes</time_frame>
    <description>frequent clinical reflux (&gt;3/day), suspicion of esophagitis (pain while eating), colics, post-prandial diarrhea (liquid stools in the first hour after meal), abdominal pain, flatulence, pallor, hypotonia, agitation, convulsions, somnolence, sweat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated pathologies</measure>
    <time_frame>1 day</time_frame>
    <description>neurologic, extremities, ribbs and vertebrales, genito-urinary, renal, cardiovascular, ano-rectal, microgastria and others. Syndromic associations are also noted, as VACTERL and charge syndroms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery details</measure>
    <time_frame>1 day</time_frame>
    <description>postponed anastomosis, difficulty or tension in the suture, colic or gastric plasty if needed, tracheoscopy realisation, visualisation or damage of the X nerve, observation of a microgastria during surgery, other relevant informations of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-surgery complications</measure>
    <time_frame>1 day</time_frame>
    <description>anastomotic leakage, mediastinitis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oesophageal Atresia</condition>
  <condition>Dumping Syndrome</condition>
  <arm_group>
    <arm_group_label>Every EA patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a one group interventional study. Every patient is included in the same arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral Glucose</intervention_name>
    <description>1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.</description>
    <arm_group_label>Every EA patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New born less than 3.5 months or age corrected for premature new born

          -  Weight ≥ 4, 150 kg

          -  Esophageal atresia (EA) type III or IV

          -  EA Surgery between May 2013 and June 2016

          -  Stop of prokinetic treatment &gt; 72 h before OGTT

          -  Information and consent of parents

          -  Patients with health insurance

        Exclusion Criteria:

          -  Age &gt; 3.5 months

          -  Weight &lt; 4.150 kg

          -  Other types of EA

          -  Dumping syndrom from other origin: microgastria, dysautonomia, small intestine surgery

          -  Other pathology that can modify glycemia: neonatal diabete, hyperinsulinism

          -  Treatment that can modify gastric motility: domperidone, erythromycin, baclofen that
             hasn't been stopped in the 72h before OGTT

          -  Absence of consent

          -  Patient judiciary protected

          -  Simultaneous participation to another clinical trial

          -  No health insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Michaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Michaud, MD</last_name>
    <email>laurent.michaud@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pellegrin - Hôpital d'Enfants,</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamireau, MD</last_name>
      <email>thierry.lamireau@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lamireau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Piolat, MD,PhD</last_name>
      <email>cpiolat@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Piolat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Michaud, MD</last_name>
      <email>laurent.michaud@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Michaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot,Unité d'Hépatogastroentérologie et Nutrition Pédiatriques</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Lachaux, MD,PhD</last_name>
      <email>alain.lachaux@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Lachaux, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huges Piloquet, MD</last_name>
      <email>hugues.piloquet@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Huges Piloquet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Chalouhi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christel Chalouhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré ,Service de chirurgie viscérale et urologique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bellaiche, MD, Phd</last_name>
      <email>marc.bellaiche@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Bellaiche, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Elbaz, MD</last_name>
      <email>frederic.elbaz@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric Elbaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Schneider, MD</last_name>
      <email>Schneider.an@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse, Hôpital Enfant</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Breton, MD</last_name>
      <email>breton.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Breton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bufler P, Ehringhaus C, Koletzko S. Dumping syndrome: a common problem following Nissen fundoplication in young children. Pediatr Surg Int. 2001 Jul;17(5-6):351-5.</citation>
    <PMID>11527163</PMID>
  </results_reference>
  <results_reference>
    <citation>Samuk I, Afriat R, Horne T, Bistritzer T, Barr J, Vinograd I. Dumping syndrome following Nissen fundoplication, diagnosis, and treatment. J Pediatr Gastroenterol Nutr. 1996 Oct;23(3):235-40.</citation>
    <PMID>8890072</PMID>
  </results_reference>
  <results_reference>
    <citation>Zung A, Zadik Z. Acarbose treatment of infant dumping syndrome: extensive study of glucose dynamics and long-term follow-up. J Pediatr Endocrinol Metab. 2003 Jul-Aug;16(6):907-15.</citation>
    <PMID>12948306</PMID>
  </results_reference>
  <results_reference>
    <citation>Ng DD, Ferry RJ Jr, Kelly A, Weinzimer SA, Stanley CA, Katz LE. Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication. J Pediatr. 2001 Dec;139(6):877-9. Review.</citation>
    <PMID>11743518</PMID>
  </results_reference>
  <results_reference>
    <citation>Michaud L, Sfeir R, Couttenier F, Turck D, Gottrand F. Dumping syndrome after esophageal atresia repair without antireflux surgery. J Pediatr Surg. 2010 Apr;45(4):E13-5. doi: 10.1016/j.jpedsurg.2010.01.016.</citation>
    <PMID>20385264</PMID>
  </results_reference>
  <results_reference>
    <citation>Holschneider P, Dübbers M, Engelskirchen R, Trompelt J, Holschneider AM. Results of the operative treatment of gastroesophageal reflux in childhood with particular focus on patients with esophageal atresia. Eur J Pediatr Surg. 2007 Jun;17(3):163-75.</citation>
    <PMID>17638154</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infants</keyword>
  <keyword>oesophageal atresia</keyword>
  <keyword>dumping syndrome</keyword>
  <keyword>prevalence</keyword>
  <keyword>Type III and IV</keyword>
  <keyword>Oral glucose tolerance test</keyword>
  <keyword>early hyperglycemia</keyword>
  <keyword>late hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dumping Syndrome</mesh_term>
    <mesh_term>Esophageal Atresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

